Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zeocin is a broad-spectrum, water-soluble, copper-chelated glycopeptide antibiotic, and a member of the bleomycin/phleomycin family isolated from the bacterium Streptomyces verticillus. It is primarily used in molecular biology for the selection of eukaryotic and prokaryotic cell lines with Zeocin resistance. Zeocin exhibits strong toxicity against bacteria, fungi (including yeast), plants, and mammalian cell lines. Its mechanism of action involves entering the cell where the copper ion is reduced and removed, activating the molecule, which then intercalates into DNA and cleaves it, leading to double-stranded DNA breaks and subsequent cell death. Resistance is conferred by the Sh ble gene product which binds Zeocin, preventing DNA cleavage. Zeocin is not intended for therapeutic or diagnostic use in humans or animals; its main application is laboratory selection in research contexts[1][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zeocin.